Stryker Co. (NYSE:SYK) is Fundsmith Investment Services LTD.'s 3rd Largest Position

Fundsmith Investment Services LTD. lifted its position in Stryker Co. (NYSE:SYK - Free Report) by 1.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,908,979 shares of the medical technology company's stock after purchasing an additional 20,163 shares during the quarter. Stryker accounts for about 8.9% of Fundsmith Investment Services LTD.'s holdings, making the stock its 3rd largest holding. Fundsmith Investment Services LTD. owned approximately 0.50% of Stryker worth $687,328,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Stryker by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after acquiring an additional 252,188 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Stryker by 0.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock valued at $4,000,056,000 after purchasing an additional 54,693 shares during the period. FMR LLC grew its holdings in shares of Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after purchasing an additional 727,850 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Stryker by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock worth $2,539,033,000 after buying an additional 168,436 shares during the period. Finally, Norges Bank bought a new stake in Stryker during the 4th quarter valued at $1,710,744,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. The trade was a 5.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Stock Down 0.4 %

Stryker stock traded down $1.59 during mid-day trading on Friday, reaching $380.87. The stock had a trading volume of 758,784 shares, compared to its average volume of 1,356,009. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a 50-day moving average price of $365.47 and a two-hundred day moving average price of $374.38. The company has a market capitalization of $145.37 billion, a price-to-earnings ratio of 49.08, a PEG ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same quarter in the prior year, the company posted $2.50 earnings per share. The business's revenue for the quarter was up 11.9% on a year-over-year basis. On average, analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's payout ratio is 45.41%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SYK shares. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Truist Financial upped their price target on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research report on Monday, May 5th. Wells Fargo & Company increased their price objective on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Finally, JMP Securities reiterated a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $427.05.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.